Christopher Raymond
Stock Analyst at Piper Sandler
(3.35)
# 1,153
Out of 5,133 analysts
139
Total ratings
53.1%
Success rate
1.82%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Upgrades: Overweight | $10 → $16 | $7.04 | +127.27% | 11 | Jan 9, 2026 | |
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $7.43 | +236.47% | 1 | Dec 18, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.90 | +165.31% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $7.38 | +292.95% | 2 | Oct 21, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $119.64 | -41.49% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $178.30 | -35.50% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.49 | +504.03% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $55.20 | +128.26% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.37 | +18.69% | 3 | Feb 11, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $220 → $227 | $220.75 | +2.83% | 12 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $454.67 | +17.23% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $758.91 | +33.48% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $24.11 | +480.67% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $67.19 | +7.17% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $2.71 | +379.70% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.91 | +848.17% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $10.97 | +592.80% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.52 | +1,834.24% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $28.81 | +14.54% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $35.28 | -37.64% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.38 | +189.86% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $324.30 | -11.19% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.80 | +47.48% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $47.26 | -40.75% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $101.17 | -60.46% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.16 | +1,644.19% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $1.60 | +5,900.00% | 2 | Mar 13, 2020 |
Ardelyx
Jan 9, 2026
Upgrades: Overweight
Price Target: $10 → $16
Current: $7.04
Upside: +127.27%
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $7.43
Upside: +236.47%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.90
Upside: +165.31%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $7.38
Upside: +292.95%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $119.64
Upside: -41.49%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $178.30
Upside: -35.50%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.49
Upside: +504.03%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $55.20
Upside: +128.26%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.37
Upside: +18.69%
AbbVie
Jan 27, 2025
Maintains: Overweight
Price Target: $220 → $227
Current: $220.75
Upside: +2.83%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $454.67
Upside: +17.23%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $758.91
Upside: +33.48%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $24.11
Upside: +480.67%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $67.19
Upside: +7.17%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $2.71
Upside: +379.70%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.91
Upside: +848.17%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $10.97
Upside: +592.80%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.52
Upside: +1,834.24%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $28.81
Upside: +14.54%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $35.28
Upside: -37.64%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.38
Upside: +189.86%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $324.30
Upside: -11.19%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.80
Upside: +47.48%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $47.26
Upside: -40.75%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $101.17
Upside: -60.46%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.16
Upside: +1,644.19%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $1.60
Upside: +5,900.00%